Market Overview:
The peptic ulcer drugs market is segmented into gastric ulcers, duodenal ulcers, and esophagitis. Gastric ulcers are the most common type of peptic ulcer, followed by duodenal ulcers. Esophagitis is inflammation of the esophagus, which can be caused by peptic acid reflux.
Global peptic ulcer drugs market size is expected to be worth around US$ 6.4 Bn by 2032 from US$ 4.6 Bn in 2022, growing at a CAGR of 3.5% during the forecast period from 2023 to 2032.
– Please check this report :@https://market.us/report/peptic-ulcer-drugs-market/
Market Recent Development:
New drug approvals: In 2022, the US Food and Drug Administration (FDA) approved vonoprazan for the treatment of Helicobacter pylori infection and erosive esophagitis. Vonoprazan is a potassium-competitive acid blocker (P-CAB), which is a new class of proton pump inhibitors (PPIs). P-CABs are more potent than traditional PPIs and work faster to reduce stomach acid.
Pipeline developments: There are a number of peptic ulcer drugs in the pipeline that are in development. Some of the most promising drugs include:
- Tegoprazan: Tegoprazan is a P-CAB that is currently in Phase 3 clinical trials for the treatment of peptic ulcers.
- Rebamipide: Rebamipide is a mucosal protective agent that is currently in Phase 3 clinical trials for the treatment of peptic ulcers.
- Lactobacillus reuteri: Lactobacillus reuteri is a probiotic that is currently in Phase 2 clinical trials for the prevention of peptic ulcers.
Market Key Players:
- Abbott
- AstraZeneca plc
- Zydus Lifesciences Limited
- Boehringer Ingelheim International GmbH
- Novitium Pharma
- Yuhan Corporation
- Pfizer Inc.
- Pharmaking Co. Ltd.
- Viatris Inc.
- RedHill Biopharma Ltd.
- Novartis AG
- Other Key Players
Regional Analysis:
-North America [United States, Canada, Mexico]
-South America [Brazil, Argentina, Columbia, Chile, Peru]
-Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
-Middle East Africa [GCC, North Africa, South Africa]
-Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]mailto:inquiry@market.us
Market Top Segmentation:
Based on Drug Type
- Proton Pump Inhibitors
- Potassium-Competitive Acid Blocker (P-CAB)
- H2-Antagonists
- Antacids
- Antibiotics
- Ulcer protective
Based on Indication
- Duodenal Ulcer
- Gastric Ulcer
- GERD (Gastroesophageal Reflux Disease)
- Gastritis
- Other Indications
Based on Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Make an inquiry before picking up this report @https://market.us/report/peptic-ulcer-drugs-market/#inquiry
Market Trends:
- Increasing prevalence of peptic ulcers
- Rising incidence of H. pylori infection
- Growing geriatric population
- Increasing awareness of peptic ulcers and their treatment options
- Launch of new and innovative peptic ulcer drugs
Contact:
Global Business Development Team – Market.us
Market.us (Powered by Prudour Pvt. Ltd.)
Send Email: inquiry@market.us
Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States
Tel: +1 718 618 4351
Website: https://market.us
